Sharekhan’s research report on Sun Pharmaceutical Industries
Q4FY21 numbers were strong with Sun Pharma reporting higher-than-expected earnings. India business growth is expected to backed by new product launches, improving the field forces productivity and expected traction in existing business. In FY21 Sun Pharma has launched 31 products, which would gather pace going ahead. The outlook for the US business has improved, following a pick-up in the lucrative specialty business with the management…
